StocksFin Logo
EXEL logo
$EXEL

Exelixis, Inc.

EXEL country of incorporation
|
https://www.exelixis.com
|
Dr. Michael Morrissey
|
954 employees
NASDAQ | Healthcare | Biotechnology
EXEL reported its Q422 earnings on February 7, 2023 (84 weeks ago).
$423.92M -6% vs. Q421 Revenues Q422
96.24% -0.9% vs. Q421 Gross Profit Margin
-7.12% ! -133.7% vs. Q421 Net Profit Margin
102.03M 48.3% vs. Q421 Free Cash Flow Q422
$-0.09 ! -131.3% vs. Q421 EPS Q422
Company Card Q422
As reported on February 7, 2023
Is profitable?
Has Revenue Growth?
Has Net Profit Growth?
Has FCF Growth?
Has OCF Growth?
Has EPS Growth?
Pays a Dividend?
Rating
B-
Growth calculated YoY
Company Card Q422
As reported on February 7, 2023
Is profitable?
Has Revenue Growth?
Has Net Profit Growth?
Has FCF Growth?
Has OCF Growth?
Has EPS Growth?
Pays a Dividend?
Rating
B-
Growth calculated YoY
Overview
Income Statement
Full Income Statement
Period Net Revenue Cost of Revenue Net Profit EPS
FY2022
1.61B
 57.91M
1.61B
$0.57
Q42022
423.92M
+3%
15.92M
-30.17M
-141.2%
$-0.09
Q32022
411.74M
-1.8%
15.31M
73.21M
+3.6%
$0.23
Q22022
419.43M
+17.8%
13.48M
70.67M
+3.1%
$0.22
Q12022
355.98M
13.2M
68.57M
$0.21
FY2021
1.43B
 52.87M
231.06M
$0.73
Q42021
451.14M
+37.4%
12.92M
95.17M
+149.1%
$0.3
Q32021
328.42M
-14.7%
11.87M
38.2M
-60.2%
$0.12
Q22021
385.18M
+42.5%
14.88M
96.09M
+5902%
$0.31
Q12021
270.23M
13.2M
1.6M
$0.01
FY2020
987.54M
 36.27M
111.78M
$0.36
FY2019
967.78M
 33.1M
321.01M
$1.06
FY2018
853.83M
 26.35M
690.07M
$2.32
Balance Sheet
Full Balance Sheet
Period Total Assets Total Liabilities Cash & Eq. Debt Stock Equity
FY2022
3.07B
 583.06M
501.2M
190.17M
2.49B
Q42022
3.07B
 583.06M
501.2M
190.17M
2.49B
Q32022
2.96B
 469.97M
675.29M
159.84M
2.49B
Q22022
2.88B
 490.14M
627M
161.02M
2.39B
Q12022
2.65B
 360.27M
723.27M
50.64M
2.29B
FY2021
2.62B
 405.62M
647.17M
51.27M
2.21B
FY2020
2.14B
 258.22M
319.22M
49.09M
1.88B
FY2019
1.89B
 199.7M
266.5M
53.47M
1.69B
FY2018
1.42B
 134.83M
314.78M
12.18M
1.29B
Cash Flow Statement
Full Cash Flow Statement
Period Operating CF Investing CF Financing CF Capex Free Cash Flow
FY 2022
362.61M
 -524.41M
586k
-27.71M
334.91M
Q42022
73.69M
 -245.78M
-2M
-1.72M
71.98M
-29.5%
Q32022
110.07M
 -68.95M
-2.04M
-8.04M
102.03M
+442.9%
Q22022
31.13M
 -135.14M
4.42M
-12.34M
18.79M
-86.8%
Q12022
147.72M
 -74.54M
205k
-5.61M
142.11M
FY2021
400.8M
 -42.88M
-14.8M
-64.23M
336.58M
FY2020
208.98M
 -131.22M
-25.13M
-30.35M
178.64M
FY2019
526.96M
 -587.25M
12.55M
-12.83M
514.12M
FY2018
415.72M
 -297.85M
9.69M
-33.3M
382.42M
Institutional Ownership
Dividend History
No dividend history.
Number of Employees